Mymetics Corporation (MYMX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 2.29: the stock has moved about 129% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerMymetics Corporation (MYMX) trades at $0.0003. Mymetics Corporation is a Swiss vaccine company focused on developing vaccines for infectious diseases. Their pipeline includes vaccine candidates for HIV-1/AIDS, Covid-19, influenza, RSV, malaria, and chikungunya. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for MYMX: MYMX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Mymetics Corporation (MYMX) Healthcare & Pipeline Overview
Mymetics Corporation, a Swiss biotechnology company founded in 1990, specializes in the research and development of virosome-based vaccines targeting infectious and life-disabling diseases. With a diverse product pipeline including HIV-1/AIDS and malaria, the company operates in a competitive landscape, collaborating with research institutions and pharmaceutical companies to advance its vaccine candidates.
What Is the Investment Thesis for MYMX?
Mymetics Corporation presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on virosome-based vaccine development for diseases like HIV-1/AIDS and malaria addresses significant unmet medical needs. However, the company's small market capitalization and negative profitability highlight its dependence on successful clinical trials and future partnerships. Key value drivers include the advancement of its vaccine candidates through clinical trials and securing partnerships with larger pharmaceutical companies. The success of these vaccines could lead to substantial revenue generation and increased market capitalization. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies with greater resources. Investors should closely monitor the progress of Mymetics' clinical trials and partnership developments to assess the company's potential for long-term growth.
Based on FMP financials and quantitative analysis
MYMX Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -0.02 reflects the company's current lack of profitability.
- Profit margin of -160166.7% indicates substantial losses relative to revenue.
- Gross margin of -47966.7% suggests high cost of goods sold or significant research and development expenses.
- Beta of 2.29 indicates higher volatility compared to the overall market, reflecting the speculative nature of biotechnology stocks.
Who Are MYMX's Competitors?
MYMX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MYMX's Key Strengths?
Virosome-based vaccine technology platform.
- Diverse vaccine pipeline targeting multiple infectious diseases.
- Collaborative partnerships with research institutions.
- Focus on addressing unmet medical needs.
What Are MYMX's Weaknesses?
Limited financial resources.
- Small number of employees.
- Dependence on successful clinical trials.
- Lack of commercialized products.
What Are the Key Risks for MYMX?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for vaccine candidates.
- Regulatory delays or rejections.
- Competition from established pharmaceutical companies.
- Limited financial resources.
- Dependence on successful partnerships.
What Are MYMX's Competitive Advantages?
- Virosome-based vaccine technology platform.
- Collaborative partnerships with research institutions and pharmaceutical companies.
- Intellectual property protection for its vaccine candidates.
- Focus on addressing unmet medical needs in infectious diseases.
What Does MYMX Do?
Mymetics Corporation, originally named ICHOR Corporation, was founded in 1990 and rebranded in July 2001. Headquartered in Epalinges, Switzerland, the company is dedicated to the research and development of innovative vaccines designed to combat infectious and life-disabling diseases. Mymetics employs a virosome-based technology platform to develop its vaccine candidates. The company's product pipeline encompasses a range of vaccines targeting critical global health challenges, including HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya. Mymetics actively engages in collaborative partnerships to advance its research and development efforts. These collaborations include agreements with the Texas Biomedical Research Institute, PATH Malaria Vaccine Initiative, and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases, focusing on the development of virosome-based vaccine formulations for a malaria transmission-blocking vaccine candidate. Additionally, Mymetics collaborates with Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. Mymetics operates within the biotechnology sector, focusing on preventative medicine through vaccine development. The company's strategy involves both internal research and external collaborations to expand its pipeline and accelerate the development of its vaccine candidates.
What Products and Services Does MYMX Offer?
- Researches and develops vaccines for infectious diseases.
- Focuses on virosome-based vaccine technology.
- Develops vaccine candidates for HIV-1/AIDS.
- Develops vaccine candidates for Covid-19.
- Develops vaccine candidates for influenza.
- Develops vaccine candidates for respiratory syncytial virus (RSV).
- Develops vaccine candidates for malaria.
- Develops vaccine candidates for chikungunya.
How Does MYMX Make Money?
- Develops vaccine candidates through internal research and development.
- Collaborates with research institutions and pharmaceutical companies.
- Seeks partnerships and licensing agreements to commercialize its vaccines.
- Generates revenue through grants, partnerships, and potential future vaccine sales.
What Industry Does MYMX Operate In?
Mymetics Corporation operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Mymetics focuses on virosome-based vaccines, a technology that offers potential advantages in terms of immunogenicity and safety. The company competes with larger pharmaceutical companies and specialized biotechnology firms, requiring strategic partnerships and successful clinical trials to gain market share.
Who Are MYMX's Key Customers?
- Governmental health organizations (e.g., WHO, national health ministries).
- Non-profit organizations focused on global health (e.g., PATH, Bill & Melinda Gates Foundation).
- Pharmaceutical companies seeking to expand their vaccine portfolios.
- Patients in need of preventative vaccines.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Mymetics Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Mymetics Corporation stands at 7.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -65.6%, showing how much profit it generates from its asset base. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Mymetics Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Epalinges, CH. The company is led by CEO Ronald Kempers. MYMX has traded publicly since 1999.
Insider Activity
12 transactions · 0 purchases, 1 sales, 11 other transactions · 5 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
MYMX Financials
MYMX Latest News
No recent news available for MYMX.
MYMX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MYMX.
Price Targets
Wall Street price target analysis for MYMX.
MYMX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MYMX; grades run from A+ (80-100) to F (below 30).
Leadership: Ronald Kempers
Unknown
He is currently managing 2 employees at Mymetics Corporation.
Track Record: Information about Ronald Kempers' track record is not available in the provided data.
MYMX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Mymetics Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, may be thinly traded, and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for fraud, lack of transparency, and limited liquidity.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume.
- Lack of transparency due to potentially limited financial reporting.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Potential for delisting or suspension of trading.
- Limited access to company information and management.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Determine the company's capital structure and debt levels.
- Understand the company's regulatory environment and compliance requirements.
- Consult with a qualified financial advisor.
- Collaborative partnerships with reputable research institutions.
- Focus on developing vaccines for significant global health challenges.
- History of research and development activities.
- Presence of intellectual property protection (patents).
- Company is registered in Switzerland.
What Investors Ask About Mymetics Corporation (MYMX) — Healthcare
What do analysts say about MYMX stock?
As of March 16, 2026, there is no available analyst coverage or consensus for Mymetics Corporation (MYMX). The company's small market capitalization and OTC listing may limit analyst interest.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on limited data available.
- OTC market data may be less reliable than major exchanges.
- CEO information is incomplete.